Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an announcement.
Clover Biopharmaceuticals Ltd. announced positive preliminary results from Phase I clinical trials for its combination vaccines targeting RSV, hMPV, and PIV3, as well as for RSV re-vaccination in older adults. The trials demonstrated promising immune responses and safety profiles, with plans to advance to Phase II trials in 2026. These developments could enhance Clover’s positioning in the vaccine market and offer new options for older adults, potentially impacting stakeholders positively.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on developing innovative vaccines and biologic therapies. The company leverages its proprietary Trimer-Tag platform technology to create combination vaccines targeting respiratory viruses, including RSV, hMPV, and PIV3.
Average Trading Volume: 22,795,260
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.63B
See more data about 2197 stock on TipRanks’ Stock Analysis page.